Vir Biotechnology (VIR) EBT Margin (2018 - 2026)

Vir Biotechnology has disclosed EBT Margin across 9 years of filings, most recently posting 432844.83% for Q1 2026.

• EBT Margin for Q1 2026 came in at 432844.83%, down 42885574.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 674.79% (up 210098.0% YoY), and the FY2025 annual result was 638.56%, up 6639.0% from the prior year.
• EBT Margin came in at 432844.83% for Q1 2026 at Vir Biotechnology, down from 67.21% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 74.8% in Q1 2022 to a low of 432844.83% in Q1 2026.
• The 5-year median for EBT Margin is 845.93% (2024), against an average of 31861.19%.
• Across the five-year window, EBT Margin surged 861301 bps in 2022 and tumbled 42885574 bps in 2026, its largest moves.
• Vir Biotechnology's EBT Margin stood at 306.9% in 2022, then sank by 134 bps to 719.35% in 2023, then dropped by 18 bps to 845.93% in 2024, then jumped by 92 bps to 67.21% in 2025, then tumbled by 643940 bps to 432844.83% in 2026.
• The last three EBT Margin figures came in at 432844.83% (Q1 2026), 67.21% (Q4 2025), and 67905.42% (Q3 2025), per Business Quant data.